ROSGQ (Rosetta Genomics) 6-Month Share Buyback Ratio: 0.00% (As of Jun. 2017 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Rosetta Genomics 6-Month Share Buyback Ratio?

Rosetta Genomics ROSGQ 6-Month Share Buyback Ratio is 0.00 as of Jun. 2017.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Rosetta Genomics's current 6-Month Share Buyback Ratio was 0.00%.

Rosetta Genomics  (OTCPK:ROSGQ) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Rosetta Genomics 6-Month Share Buyback Ratio Related Terms

ROSGQ vs TEAR, IDTA, ABMC: 6-Month Share Buyback Ratio Comparison

For the Diagnostics & Research subindustry, Rosetta Genomics's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rosetta Genomics 6-Month Share Buyback Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's 6-Month Share Buyback Ratio falls into.


Rosetta Genomics 6-Month Share Buyback Ratio Calculation

Rosetta Genomics's 6-Month Share Buyback Ratio for the quarter that ended in Jun. 2017 is calculated as

6-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Dec. 2016 ) - Shares Outstanding (EOP) (Jun. 2017 )) / Shares Outstanding (EOP) (Dec. 2016 )
=(1.844 - 2.588) / 1.844
=-40.35%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 6-Month Share Buyback Ratio of 0.00 mean?
Rosetta Genomics (ROSGQ) has a 6-Month Share Buyback Ratio of 0.00 as of Jun. 2017. The 6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. View historical data for Rosetta Genomics and its competitors.
Is Rosetta Genomics' 6-Month Share Buyback Ratio too high?
Rosetta Genomics' current 6-Month Share Buyback Ratio is 0.00.
How does Rosetta Genomics' 6-Month Share Buyback Ratio compare to TEAR and IDTA?
Rosetta Genomics' 6-Month Share Buyback Ratio of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 6-Month Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 6-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Share Buyback Ratio mean?
A high 6-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. View historical data for Rosetta Genomics and its competitors. Rosetta Genomics's current 6-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current 6-Month Share Buyback Ratio of 0.00. The current 6-Month Share Buyback Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Share Buyback Ratio calculated?
6-Month Share Buyback Ratio is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current 6-Month Share Buyback Ratio is 0.00 as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.